<DOC>
	<DOCNO>NCT01381913</DOCNO>
	<brief_summary>Because locally far-advanced gastric cancer combine adjacent tissue invasion poor prognosis , phase 2 3 clinical trial neoadjuvant chemotherapy ( NAC ) perform Japan . However , neoadjuvant chemoradiotherapy ( NACRT ) achieve superior local tumor control compare NAC . This feasibility trial explore feasibility safety neoadjuvant chemoradiotherapy ( NACRT ) type gastric cancer .</brief_summary>
	<brief_title>Feasibility Trial Neoadjuvant Chemoradiotherapy Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>Since S-1 ( combine drug tegafur , 5-chloro-2,4-dihydroxypyridine potassium oxonate ) approve Japan 1999 large-scale clinical trial , adjuvant chemotherapy S-1 standard treatment stage II/III gastric cancer . However , far-advanced gastric cancer , various adjuvant chemotherapy , include S-1 , achieve satisfactory result . Therefore , Japan Clinical Oncology Group ( JCOG ) currently perform phase 2 3 clinical trial neoadjuvant chemotherapy ( NAC ) locally far-advanced gastric cancer . However , previous study NAC report pathological response rate 15-50 % main lesion , indicate significant effect local tumor control . On hand , study report anticancer drug , include S-1 , radiosensitizing effect , neoadjuvant chemoradiotherapy ( NACRT ) achieve superior local tumor control compare NAC . Therefore , conduct feasibility trial NACRT S-1 locally far-advanced gastric cancer combine adjacent tissue invasion .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically proven gastric adenocarcinoma Tumor invasion adjacent structure ( T4 ) and/or tumor bulky nodal metastases No metastasis outside Group 2 lymph node Neither peritoneal metastasis liver metastasis No distant metastasis An Eastern cooperative oncology group performance status 0 2 No prior radiation therapy Sufficient organ function A synchronous previously active malignancy Insufficient oral intake A history severe allergy Watery diarrhea Severe comorbidities Requiring therapy pericardial effusion pleural effusion Contraindications S1 radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Adjacent tissue invasion</keyword>
	<keyword>Feasibility trial</keyword>
</DOC>